Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Feb 19, 2009

165_ip_2009-02-19_d5b42998-14e7-4fa0-8910-46373aa6b6ae.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Fourth Quarter / Fiscal Year 2008 Earnings

Analyst Meeting, February 19, 2009

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detailed in the Company's reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Regulation G: The following slides might contain summary information about Fresenius Medical Care AG & Co. KGaA sales, gross profit, operating income, net Income, and earnings per share for the fourth quarter and fiscal 2008, and the comparable period of 2007, which information is presented on a "non-GAAP financial measures" basis rather than in accordance with U.S. generally accepted accounting principles (GAAP). Please review Fresenius Medical Care's investor news dated February 19, 2009, for information on the Company's operating income, net income and earnings per share for these periods presented on a GAAP basis. Such GAAP-basis information will also be contained in the Company's reports on Form 20-F of Form 6-K to be filed with or furnished to the U.S. Securities and Exchange Commission.

1. Business Update

2. Financials and Outlook

3. Q&A Session

Another Year of Value-Building

h
t
R
d
f
i
i
l
l
d
1
2
i
d
i
i
d
d
i
t
t
•
e
c
o
r
n
a
n
c
a
r
e
s
u
s
a
n
c
o
n
s
e
c
u
v
e
v
e
n
n
c
r
e
a
s
e
A
l
d
i
h
f
%
t
t
7
•
c
c
e
e
r
a
e
o
r
g
a
n
c
g
r
o
w
o
E
d
d
d
i
i
i
l
d
i
d
t
t
•
x
p
a
n
e
p
r
o
u
c
o
n
c
a
p
a
c
e
s
w
o
r
w
e
S
h
d
l
d
t
t
t
•
r
e
n
g
e
n
e
r
e
n
a
r
u
g
s
e
g
m
e
n
2
0
0
9
d
2
0
1
0
i
b
i
d
i
i
l
f
i
d
h
t
t
t
t
•
a
n
s
r
a
e
g
c
s
n
e
s
s
r
e
r
s
n
p
a
c
e
o
r
s
s
a
n
e
g
r
o
u
v
u
w

Achieved Record Results in 2008

despite increased costs and very volatile currency environment

R
e
e
n
e
v
u		 \$
1		 0
6
1
2
m
,		 9
%
+
i
O
h
t
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 %
7
+
N
i
t
e
n
c
o
m
e		 \$ 8
1
8
m		 %
1
4
+
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$ 2
5
7		 1
3
%
+

Fiscal Year 2008 – Revenue

Fiscal Year 2008 - Dialysis Services Global

Strong Growth of 6% constant currency

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 F
Y
2
0
0
7		 F
Y
2
0
0
8		 G
t
h
r
o
w		 c
c
i
N
h
A
t
o
r
m
e
r
c
a		 6
0
0
2
,		 6
2
4
7
,		 %
4
i
I
l
t
t
n
e
r
n
a
o
n
a		 1
2
1
1
,		 1
4
9
0
,		 2
3
%		 1
8
%
T
l
t
o
a		 2
1
3
7
,		 3
7
7
7
,		 %
7		 6
%

Treating more than 185,700 patients in around 2,400 clinics *

cc = constant currency * including managed clinics and clinics where FME has more than 10% share

Very Strong External Product Growth of 11%cc

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 F
Y
2
0
0
7		 F
Y
2
0
0
8		 G
h
t
r
o
w		 c
c
T
l
R
t
o
a
e
v
e
n
u
e
(
inc
l.
In
l
Re
)
te
rn
a
ve
nu
e		 3
2
7
8
,		 3
7
2
8
,		 %
1
4		 %
1
0
E
l
R
t
e
r
n
a
e
e
n
e
x
v
u		 2
0
5
7
,		 5
2
8
7
,		 1
%
5		 1
1
%
N
t
h
A
i
o
r
m
e
r
c
a		 6
6
1		 5
7
8		 1
%
5
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
8
4
6
,		 2
1
1
7
,		 %
1
5		 %
1
0

Product Growth clearly above market in North America and International

Q4 2008 – Revenue

Q4 2008 - Dialysis Services - Global

Strong Growth of 9% constant currency

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
7		 Q
4
2
0
0
8		 G
h
t
r
o
w		 c
c
N
h
A
i
t
o
r
m
e
r
c
a		 1
2
6
5
,		 1
6
3
2
,		 %
7
I
i
l
t
t
n
e
r
n
a
o
n
a		 3
3
0		 3
5
2		 6
%		 1
8
%
T
l
t
o
a		 1
8
5
6
,		 1
9
8
4
,		 %
7		 %
9

Continued double digit growth at constant currency in International

Excellent Performance in Key Metrics

Q
4
2
0
0
8		 T
l
t
o
a		 N
h
A
i
I
i
l
t
t
t
o
r
m
e
r
c
a
n
e
r
n
a
o
n
a
i
O
h
t
r
g
a
n
c
r
e
e
n
e
g
r
o
v
u
w		 8
%
+		 6
%
+		 1
8
%
+
S
k
h
t
t
t
t
t
a
m
e
m
a
r
e
r
e
a
m
e
n
g
r
o
w		 5
%
+		 3
%
+		 1
0
%
+
R
t
t
t
e
e
n
e
p
e
r
r
e
a
m
e
n
v
u		 1
)
\$
3
3
0		 \$
1
5
4
G
t
h
r
o
w		 3
%
+		 %
7
+
c
c
F
i
l
Y
2
0
0
8
s
c
a
e
a
r
f
N
b
l
i
i
u
m
e
r
o
c
n
c
s		 2
3
8
8
,		 1
6
8
6
,		 7
0
2
G
t
h
r
o
w		 %
7
+		 %
5
+		 1
0
%
+
D
F
Y
e
n
o
v
o
s
(
)
in
lu
d
in
d
l
in
ic
c
g
m
a
na
g
e
c
s		 1
2
9		 8
1		 4
8

1) including Mexico

2008 – Revenue per treatment - US

Overall Strong Quality Performance

N
h
A
i
t
o
r
m
e
r
c
a		 I
t
n
e
r
n		 i
l
t
a
o
n
a
%
f
F
M
E
i
t
t
o
p
a
e
n
s		 Q
4
2
0
0
7		 Q
4
2
0
0
8		 Q
4
2
0
0
7		 Q
4
2
0
0
8
K
/
V
1
2
t
≥		 9
%
5		 9
5
%		 9
%
5		 9
5
%
1
1
/
H
l
b
i
d
l
≥
e
m
o
g
o
n
g		 8
0
%		 7
3
%		 1
%
7		 6
9
%
/
H
l
b
i
1
0
1
3
d
l
e
m
o
g
o
n
g
=
-		 %
8
0		 8
5
%		 %
7
4		 7
5
%
A
l
b
i
3
5
/
d
l
≥
m
n
g
u		 8
0
%		 8
0
%		 8
7
%		 8
5
%
P
h
h
3
/
d
l
t
5
5
5
o
s
p
a
e
m
g
-		 2
%
5		 5
3
%		 6
0
%		 6
1
%
H
i
t
l
i
t
i
d
o
s
p
a
z
a
o
n
a
y
s		 *
9
9		 *
5
1
0		 8
7		 8
6

* The hospitalization rates for the US reflects FMS adoption of CMS policy

Q4 2008 - Dialysis Products - Global

External Product Growth of 12%cc

\$
S
U
i
i
l
l
i
n
m
o
n
s
-		 Q
4
2
0
0
7		 Q
4
2
0
0
8		 G
t
h
r
o
w		 c
c
T
l
R
t
o
a
e
e
n
e
v
u
(
inc
l.
In
te
l
Re
)
rn
a
ve
nu
e		 9
1
8		 9
6
4		 %
5		 1
2
%
E
l
R
t
x
e
r
n
a
e
v
e
n
u
e		 1
3
7		 3
8
7		 4
%		 1
2
%
N
t
h
A
i
o
r
m
e
r
c
a		 1
8
0		 2
2
0		 2
2
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 5
3
3		 5
1
8		 (
%
)
3		 %
8

2009 / 2010 Strategic Business Drivers

Revenue Drivers for Sustained 6 - 9% Growth

D
i		 l
i
M
k
D
i
t
a
y
s
s
a
r
e
r
v
e
r
s
:
ƒ G
%
P
t
i
t
t
h
6
Y
a
e
n
r
o
w
p
e
r
e
a
r
~
ƒ S
b
l
P
i
i
D
i
l
i
R
i
b
b
d
Q
l
i
P
i
t
t
t
t
t
t
t
a
e
o
o
s
e
a
s
s
e
m
r
s
e
m
e
n
a
s
e
o
n
a
a
e
n
v
y
u
u
y
O
t
c
o
m
e
s
u

Expansion & New Product Launches:

  • Renal Pharma
  • Clinic Acquisitions
  • Integrated Care Model
  • New Renal Product Launches worldwide in HD and PD

Analyst Meeting February 19, 2009 © 2009 Fresenius Medical Care AG & Co. KGaA 16

1. Business Update

2. Financials and Outlook

3. Q&A Session

Achieved All Key Metrics

i
d
G
a
n
c
e
u		 R
d
t
e
p
o
r
e
\$
R
(
)
e
e
n
e
m
v
u		 1
0
4
0
0
>
,		 1
0
6
1
2
,		 9
\$
(
)
N
t
i
e
n
c
o
m
e
m		 8
0
5
8
2
5
–		 8
1
8		 9
T
l
D
b
/
E
B
I
D
T
A
t
t
o
a
e		 2
8
<		 2
6
9		 9
\$
C
i
l
E
d
i
(
)
t
t
a
p
a
p
e
n
r
e
s
m
x
u		 6
5
0
7
5
0
–		 6
3
7		 9
\$
A
i
i
i
(
)
t
c
q
s
o
n
s
m
u		 1
0
2
0
5
5
–		 2
1
8		 9
\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
7		 F
Y
2
0
0
8		 G
t
h
r
o
w
N
t
e
r
e
e
n
e
v
u		 9
2
0
7
,		 1
0
6
1
2
,		 *
9
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 1
5
8
0
,		 1
6
7
2
,		 %
6
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
6
3		 1
5
8
I
t
t
t
n
e
r
e
s
e
x
p
e
n
s
e
n
e
,		 3
7
1		 3
3
6
f
I
b
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 1
2
0
9
,		 1
3
3
6
,		 1
0
%
I
T
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 6
6
4		 4
8
9
T
t
a
x
r
a
e		 %
3
9		 %
3
7
M
i
i
t
i
t
t
n
o
r
y
n
e
r
e
s		 2
6		 2
9
N
t
i
e
n
c
o
m
e		 7
1
7		 8
1
8		 1
4
%

* 8% growth at constant currency, 7% organic growth

\$
i
i
l
l
i
n
m
o
n
s		 Q
4
2
0
0
7		 Q
4
2
0
0
8		 G
h
t
r
o
w
N
t
e
r
e
v
e
n
u
e		 2
5
6
9
,		 2
7
2
2
,		 *
6
%
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 4
2
8		 4
3
3		 1
%
%
E
B
I
T
i
i
m
a
r
g
n
n		 1
6
6		 1
5
9
I
t
t
t
n
e
r
e
s
e
p
e
n
s
e
n
e
x
,		 9
0		 8
5
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 3
3
8		 3
4
8		 %
3
I
T
n
c
o
m
e
a
e
p
e
n
s
e
x
x		 1
3
5		 1
2
4
T
t
a
x
r
a
e		 4
0
%		 3
6
%
M
i
i
t
i
t
t
n
o
r
y
n
e
r
e
s		 6 1
0
N
i
t
e
n
c
o
m
e		 1
9
7		 2
1
4		 9
%

* 10% growth at constant currency, 9% organic growth

2004 - 2008 –Operating Margin Development

Days Sales Outstanding (DSO)

Benchmark in Industry

Operating Cash Flow 10% of Revenues

\$
i
i
l
l
i
n
m
o
n
s		 F
Y
2
0
0
7		 F
Y
2
0
0
8		 G
t
h
r
o
w
1)
O
i
C
h
F
l
t
p
e
r
a
n
g
a
s
o
w		 1
2
0
0
,		 1
0
1
6
,		 (
1
%
)
5
1)
C
i
t
l
E
d
i
t
t
a
p
a
x
p
e
n
u
r
e
s
n
e
,		 (
5
4
3
)		 (
)
6
7
3
F
C
h
F
l
r
e
e
a
s
o
w		 6
5
7		 3
4
3		 (
%
)
4
8
1)
A
i
i
i
t
f
d
i
i
c
q
s
o
n
s
t
t
t
u
n
e
o
v
e
s
u
r
e
s
,		 (
2
3
4
)		 (
)
2
1
8
C
F
h
F
l
f
t
i
i
t
i
r
e
e
a
s
o
w
a
e
r
a
c
q
s
o
n
s
u
,		 4
2
3		 1
2
5

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Operating Cash Flow 11% of Revenues

\$
i
i
l
l
i
n
m
o
n
s		 Q
4
2
0
0
7		 Q
4
2
0
0
8		 G
h
t
r
o
w
1)
O
C
t
i
h
F
l
p
e
r
a
n
g
a
s
o
w		 3
0
9		 3
0
1		 (
3
%
)
1)
C
i
l
E
d
i
t
t
t
a
p
a
x
p
e
n
u
r
e
s
n
e
,		 (
)
1
8
3		 (
)
1
8
1
F
C
h
F
l
r
e
e
a
s
o
w		 1
2
6		 1
2
0		 (
%
)
5
1)
A
i
i
t
i
t
f
d
i
t
i
t
c
q
u
s
o
n
s
n
e
o
v
e
s
u
r
e
s
,		 (
1
1
9
)		 (
)
8
8
F
C
h
F
l
f
t
i
i
t
i
r
e
e
a
s
o
w
a
e
r
a
c
q
u
s
o
n
s
,		 7 3
2

1) A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Fiscal Year 2008 - Debt / EBITDA Development

* including non-cash charges and excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

A 10% Appreciation in Currencies versus the US-Dollar would result in the following impacts on the Earnings after Tax

Fiscal Year 2009 – Outlook

\$
U
S
i
i
l
l
i
n
m
o
n
s
-		 G
i
d
a
n
c
e
u
N
t
R
e
e
v
e
n
u
e
s		 \$
1
1
1
0
0
>
,
N
I
t
e
n
c
o
m
e		 \$
8
0
8
9
0
5
–
L
t
i
e
v
e
r
a
g
e
r
a
o
(
/
)
D
b
t
E
B
I
T
D
A
e		 2
7
<
C
i
l
E
d
i
t
t
a
p
a
p
e
n
r
e
s
x
u		 \$
5
5
0
6
5
0
~
-
A
i
i
i
t
c
q
u
s
o
n
s		 \$
2
0
0
3
0
0
~
-

XNet income range widened due to increased currency volatility

X Measured in Euros (€), the guidance range is fully in line with mid-term guidance

Thank You for your interest in Fresenius Medical Care !

1. Business Update

2. Financials and Outlook

3. Q&A Session

Fresenius Medical Care

The World's Leading Renal Therapy Company

Fourth Quarter / Fiscal Year 2008 Earnings

Analyst Meeting, February 19, 2009

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

D
b
t
e		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4
1
)
S
ho
bo
in
(
in
l.
A
/
R
)
t
te
r
rm
rro
w
g
s
c
p
ro
g
ra
m		 6
8
4		 2
1
7		 3
3
1		 5
1
1		 4
1
9
S
ho
bo
in
fro
la
d
ies
t
te
te
t
+
r
rm
rro
w
g
s
m
re
p
ar		 1 2 5 1
9		 6
Cu
io
f
lo
de
b
d
i
l
lea
b
l
ig
io
t p
t
-te
t a
ta
t
+
rre
n
or
n
o
ng
rm
n
ca
p
se
o
a
ns		 4
5
5		 8
5		 1
6
0		 1
2
6		 2
3
0
Cu
io
f
Tr
Pr
fe
d
Se
i
ies
t p
t
t
t
rre
n
or
n
o
us
e
rre
cu
r
+		 0 6
7
0
Lo
de
b
d
i
l
lea
b
l
ig
io
-te
t a
ta
t
ng
rm
n
ca
p
se
o
a
ns
+
,
les
io
t p
t
s
cu
rre
n
or
n		 3,
9
5
7		 4,
0
0
4		 3,
8
2
9		 7
0
7		 5
4
5
fe
Se
i
ies
(
f c
io
)
Tr
t
Pr
d
t
t o
t p
t
us
e
rre
cu
r
ne
ur
re
n
or
n
+		 6
4
1		 6
6
4		 1,
2
5
4		 1,
1
8
8		 1,
2
7
9
To
ta
l
de
b
t
=		 5,
7
3
8		 5,
6
4
2		 5,
5
7
9		 2,
1
9
1		 2,
4
7
9
E
B
I
T
D
A		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 2
)
F
Y
2
0
0
6
(
for
)
p
ro
ma		 F
Y
2
0
0
5		 F
Y
2
0
0
4
La
lve
hs
in
in
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
g
co
m
e		 1,
6
7
2		 1,
5
8
0		 1,
3
6
7		 9
3
9		 8
5
2
La
lve
hs
de
ia
io
d
iza
io
t
tw
t
t
t
t
+
s
e
m
on
p
re
c
n
an
am
or
n		 4
1
6		 3
6
3		 3
2
6		 2
5
1		 2
3
3
No
h
ha
+
n-
ca
s
c
rg
es		 4
4		 4
1		 3
5		 1
4		 1
3
E
B
I
T
D
A
(
l
ize
d
)
=
an
nu
a		 2,
1
3
2		 1,
9
8
4		 1,
7
2
8		 1,
2
0
4		 1,
0
9
8

1) A/R securitization program off-balance sheet in 2003 and included in short term borrowings from 2004 onwards

2) Excluding restructuring costs and in-process R&D

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 h
t
g
ro
w		 cc Q
4
2
0
0
8		 Q
4
2
0
0
7		 h
t
g
ro
w		 cc
I
i
l
du
t
t
t
n
e
r
n
a
o
n
a
p
ro
c
re
ve
nu
e		 2,
4
1
9		 2,
0
9
9		 1
5
%
+		 1
0
%
+		 5
9
2		 6
0
8		 3
%
-		 9
%
+
In
l r
te
rn
a
ev
e
nu
e
-		 (
3
0
2
)		 (
2
5
3
)		 (
7
4
)		 (
7
5
)
Ex
l
t
e
r
n
a
r
e
v
e
nu
e
=		 2,
1
1
7		 1,
8
4
6		 1
5
%
+		 1
0
%
+		 5
1
8		 5
3
3		 3
%
-		 8
%
+
N
h
A
i
du
t
t
o
r
m
e
r
c
a
p
ro
c
re
ve
nu
e		 1,
3
0
9		 1,
1
9
7		 1
1
%
+		 3
1
7		 3
1
0		 2
0
%
+
In
l r
te
rn
a
ev
e
nu
e
-		 (
1
)
5
5		 (
1
8
)
5		 (
1
1
)
5		 (
1
3
0
)
Ex
l
t
e
r
n
a
r
e
v
e
nu
e
=		 5
8
7		 6
6
1		 1
5
%
+		 2
2
0		 1
8
0		 2
2
%
+
T
O
T
A
L
du
t r
p
ro
c
ev
e
nu
e		 3,
7
2
8		 3,
2
7
8		 1
4
%
+		 1
0
%
+		 9
6
4		 9
1
8		 5
%
+		 1
2
%
+
In
te
l r
rn
a
ev
e
nu
e
-		 (
8
5
3
)		 (
7
7
1
)		 (
2
2
6
)		 (
2
0
5
)
Ex
l
t
e
r
n
a
r
e
e
nu
e
v
=		 2,
8
7
5		 2,
5
0
7		 1
5
%
+		 1
1
%
+		 7
3
8		 7
1
3		 4
%
+		 1
2
%
+
C
i
l
d
i
(
)
t
t
t
a
p
a
e
p
e
n
r
e
n
e
x
u		 F
Y
2
0
0
8		 F
Y
2
0
0
7		 Q
4
2
0
0
8		 Q
4
2
0
0
7
f p
Pu
ha
ty
la
t a
d
ip
t
rc
s
e
o
ro
p
e
r
p
n
n
e
q
u
m
e
n
,		 6
8
7		 5
7
3		 1
8
5		 1
9
2
fro
f p
Pr
d
le
ty
la
t a
d
ip
t
o
c
e
e
s
m
s
a
o
ro
p
e
r
p
n
n
e
q
u
m
e
n
-
,		 (
)
1
4		 (
)
3
0		 (
)
4		 (
)
9
C
i
l
d
i
(
)
t
tu
t
a
p
a
e
x
p
e
n
r
e
n
e
=		 6
7
3		 5
4
3		 1
8
1		 1
8
3

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

C
h
F
l
a
s
o
w		 Q
4
2
0
0
8		 Q
4
2
0
0
7		 F
Y
2
0
0
8		 F
Y
2
0
0
7
Ac
is
i
io
d
In
d
ha
f
in
i
b
le
t
tm
t a
t p
ta
ts
q
u
ns
a
n
ve
s
e
n
n
ne
u
rc
s
e
s
o
ng
a
s
s
e		 (
1
0
1
)		 (
1
1
9
)		 (
2
7
7
)		 (
2
6
3
)
Pr
d
fro
d
ive
t
i
tu
o
c
e
e
s
m
s
re
s		 1
3		 - 5
9		 2
9
A
i
i
i
f
d
iv
i
t
t
t
tu
c
q
u
s
o
n
s,
n
e
o
e
s
r
e
s		 (
8
8
)		 (
1
1
9
)		 (
2
1
8
)		 (
2
3
4
)
N
i
t
e
n
c
o
m
e		 1
9
9
8		 1
9
9
9		 2
0
0
1
Ne
in
t
c
o
m
e		 1
9		 (
2
4
9
)		 6
3
Lo
fro
d
is
in
d
io
d
la
ive
f
fe
f a
in
ha
t
t
t
t o
t
s
s
m
c
o
n
e
o
p
e
ra
ns
a
n
cu
m
e
c
c
c
ou
n
g
c
ng
e
u
u		 1
1
3
S
ia
l c
ha
fo
le
f
in
ig
io
d
la
d
f
t
t
t o
t
t
te
ts
t o
ta
p
e
c
rg
e
r s
e
m
e
n
ve
s
a
ns
a
n
re
c
o
s
ne
xe
s
,		 4
1
9
\$
\$
S
ia
l c
ha
fo
1
9
9
6
la
te
d
le
l m
t
te
f
2
5
8
(
1
7
7m
t o
f
ta
)
p
e
c
rg
e
r
m
e
rg
e
r r
e
g
a
a
rs
o
m
n
e
xe
s
\$
\$
f
(
f
)
d
la
te
d
io
te
7m
4m
t o
ta
a
n
re
p
r
r q
a
r
r e
xp
e
ns
e
s
o
ne
xe
s
u
,		 1
8
2
N
i
d
j
d
t
t
e
n
c
o
m
e,
a
u
s
e		 1
3
2		 1
0
7		 2
4
5
F
Y
2
0
0
8		 C
l
i
i
n
c		 P
i
t
t
a
e
n
s		 T
t
t
r
e
a
m
e
n
s
(
in
i
l
l
io
)
m
n
T
t
l
o
a		 2
3
8
8
,		 1
8
4
0
8
6
,		 2
7
9
G
t
h
r
o
w		 %
7
+		 6
%
+		 %
5
+
N
t
h
A
i
o
r
m
e
r
c
a		 1
6
8
6
,		 1
2
8
5
5
7
,		 1
9
1
G
h
t
r
o
w		 5
%
+		 4
%
+		 4
%
+
I
t
t
i
l
n
e
r
n
a
o
n
a		 7
0
2		 5
8
2
2
9
,		 8
7
G
h
t
r
o
w		 1
0
%
+		 1
1
%
+		 9
%
+
E
r
o
p
e
u		 4
0
0		 2
9
8
4
1
,		 4
5
L
i
A
i
t
a
n
m
e
r
c
a		 1
7
7		 1
9
2
3
0
,		 2
9
A
i
P
i
f
i
s
a
a
c
c
-		 1
2
5		 9
1
5
8
,		 1
3

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Oliver MaierHead of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Email: [email protected]

Terry L. Morris Tel.: +1-800-948-2538Fax.: +1-615-345-5605Email: [email protected]

Gerrit JostTel.: +49-(0)6172-609-5216 Fax.: +49-(0)6172-609-2301 Email: [email protected] Ordinary shares WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

For recent updates, please have a look at our webpage. Navigation around www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our Share

More from Fresenius Medical Care AG & Co. KGaA

Regulatory Filings 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.